Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVZ Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme
NCT02177578Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2014
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial in glioblastoma multiforme (GBM) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Change from Baseline to Initial Progression at 24 months. Started Jul 2014; status: active, not recruiting.
02
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02177578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177578.